文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

DRviaSPCN:一种通过亚通路串扰网络进行癌症药物重定位的软件包。

DRviaSPCN: a software package for drug repurposing in cancer via a subpathway crosstalk network.

机构信息

College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.

出版信息

Bioinformatics. 2022 Oct 31;38(21):4975-4977. doi: 10.1093/bioinformatics/btac611.


DOI:10.1093/bioinformatics/btac611
PMID:36066432
Abstract

SUMMARY: Drug repurposing is an approach used to discover new indications for existing drugs. Recently, several computational approaches have been developed for drug repurposing in cancer. Nevertheless, no approaches have reported a systematic analysis of pathway crosstalk. Pathway crosstalk, which refers to the phenomenon of interaction or cooperation between pathways, is a critical aspect of tumor pathways that allows cancer cells to survive and acquire resistance to drug therapy. Here, we innovatively developed a system biology R-based software package, DRviaSPCN, to repurpose drugs for cancer via a subpathway (SP) crosstalk network. This package provides a novel approach to prioritize cancer candidate drugs by considering drug-induced SPs and their crosstalk effects. The operation modes mainly include construction of the SP network and calculation of the centrality scores of SPs to reflect the influence of SP crosstalk, calculation of enrichment scores of drug- and disease-induced dysfunctional SPs and weighted them by the centrality scores of SPs, evaluation of the drug-disease reverse association at the weighted SP level, identification of cancer candidate drugs and visualization of the results. Its capabilities enable DRviaSPCN to find cancer candidate drugs, which will complement the recent tools which did not consider crosstalk among pathways/SPs. DRviaSPCN may help to facilitate the development of drug discovery. AVAILABILITY AND IMPLEMENTATION: The package is implemented in R and available under GPL-2 license from the CRAN website (https://CRAN.R-project.org/package=DRviaSPCN). SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

摘要

摘要:药物重定位是一种用于发现现有药物新适应症的方法。最近,已经开发了几种用于癌症药物重定位的计算方法。然而,还没有方法报道对途径串扰进行系统分析。途径串扰是指途径之间相互作用或合作的现象,是肿瘤途径的一个关键方面,使癌细胞能够存活并获得对药物治疗的抗性。在这里,我们创新性地开发了一个基于系统生物学 R 的软件包 DRviaSPCN,通过亚途径(SP)串扰网络来重新定位癌症药物。该软件包提供了一种通过考虑药物诱导的 SP 和它们的串扰效应来优先考虑癌症候选药物的新方法。操作模式主要包括 SP 网络的构建和 SP 中心性得分的计算,以反映 SP 串扰的影响,计算药物和疾病诱导的功能失调 SP 的富集得分,并通过 SP 的中心性得分对其进行加权,在加权 SP 水平上评估药物-疾病反向关联,识别癌症候选药物并可视化结果。DRviaSPCN 的功能使其能够找到癌症候选药物,这将补充最近没有考虑途径/SP 之间串扰的工具。DRviaSPCN 可能有助于促进药物发现的发展。

可用性和实现:该软件包在 R 中实现,并在 CRAN 网站(https://CRAN.R-project.org/package=DRviaSPCN)上以 GPL-2 许可证提供。

补充信息:补充数据可在生物信息学在线获得。

相似文献

[1]
DRviaSPCN: a software package for drug repurposing in cancer via a subpathway crosstalk network.

Bioinformatics. 2022-10-31

[2]
SubtypeDrug: a software package for prioritization of candidate cancer subtype-specific drugs.

Bioinformatics. 2021-8-25

[3]
psSubpathway: a software package for flexible identification of phenotype-specific subpathways in cancer progression.

Bioinformatics. 2020-4-1

[4]
Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities.

Mol Oncol. 2019-8-21

[5]
A novel computational approach for drug repurposing using systems biology.

Bioinformatics. 2018-8-15

[6]
CNA2Subpathway: identification of dysregulated subpathway driven by copy number alterations in cancer.

Brief Bioinform. 2021-9-2

[7]
wTO: an R package for computing weighted topological overlap and a consensus network with integrated visualization tool.

BMC Bioinformatics. 2018-10-24

[8]
DrugSim2DR: systematic prediction of drug functional similarities in the context of specific disease for drug repurposing.

Gigascience. 2022-12-28

[9]
Repurposing drugs in oncology: From candidate selection to clinical adoption.

Semin Cancer Biol. 2021-1

[10]
Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing.

Bioinformatics. 2019-8-15

引用本文的文献

[1]
Strategies for robust, accurate, and generalizable benchmarking of drug discovery platforms.

bioRxiv. 2024-12-16

[2]
DrugRepoBank: a comprehensive database and discovery platform for accelerating drug repositioning.

Database (Oxford). 2024-7-11

[3]
Integrated edge information and pathway topology for drug-disease associations.

iScience. 2024-5-18

[4]
DrugSim2DR: systematic prediction of drug functional similarities in the context of specific disease for drug repurposing.

Gigascience. 2022-12-28

[5]
Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing.

BMC Bioinformatics. 2023-5-24

[6]
DTSEA: A network-based drug target set enrichment analysis method for drug repurposing against COVID-19.

Comput Biol Med. 2023-6

[7]
A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma.

Comput Struct Biotechnol J. 2023-4-11

[8]
Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy.

J Transl Med. 2022-12-23

[9]
Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic Pathway Signatures.

Genes (Basel). 2022-10-29

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索